July 19 Clinical Quick Takes: Polyphor closes Phase III murepavadin trials; plus Takeda and Alector

Polyphor ends PRISM trials
The Swiss immuno-oncology company Polyphor AG (SIX:POLN) closed the Phase III PRISM MDR and PRISM UDR trials of its IV formulation of murepavadin for hospital-acquired and ventilator-associated

Read the full 308 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE